Treatment of Hepatic Encephalopathy in Covert or Minimal Disease (CHE / MHE)
Covert and minimal hepatic encephalopathy represent the subclinical end of the HE spectrum. Because these patients have no overtly visible symptoms, the condition is missed without dedicated testing — yet impairment is present and treatable.
Clinical Scenario
Patients present with minimal or grade 1 hepatic encephalopathy (covert HE), with no overt HE (grade 2 or higher). The diagnosis is established exclusively through specialized neuropsychological or neurophysiological testing. MHE is the subclinical form of HE that can only be identified through such testing; CHE is defined by excluding overt HE in the appropriate clinical context, given the low reproducibility of its clinical diagnosis.
Treatment Approach
An oral agent is the suggested first-line treatment for this population, supported by evidence showing improvement in neuropsychological outcomes. Treatment is conducted as a defined, limited-duration trial, with clear symptom-based response criteria established before starting.
Complete regimen, alternative options, and full theragnostic trial criteria are in the structured protocol →
Clinical Goals
The primary aims are improvement in neuropsychological test results and reversal of minimal hepatic encephalopathy. Adherence and potential symptom improvement are assessed 4–8 weeks after prescription to inform whether to continue treatment.
References
DOI: 10.14309/ajg.0000000000003899
- MHE is the subclinical form of HE that can only be identified through specialized neuropsychological or neurophysiological testing.
- Given the low reproducibility of clinical diagnosis of CHE (minimal or grade 1 HE), CHE should be defined by excluding OHE (grade 2 or higher) in the appropriate clinical context.
- In patients with MHE/CHE, we suggest treatment with lactulose vs no treatment (conditional recommendation, low certainty of evidence).
- Cognitive testing for CHE/MHE and subsequent therapy with lactulose or rifaximin may improve health-related quality of life.
- Almost universally, improvement in neuropsychological tests has been reported, including a higher MHE reversal rate, when compared with control group/placebo.
- Whenever a theragnostic approach with lactulose is attempted, it should be followed by an evaluation of adherence and potential symptom improvement 4–8 wk after prescription, to inform continuation or not.
View source ↗